<h3>Title</h3>
<h3><span style="color: #0000ff;">A Ruthenium (II)-Ferrocene hetero bimetallic anticancer agent circumvents cisplatin resistance</span></h3>
<p><strong><span style="text-decoration: underline;">Abstract</span> :</strong></p>
<p>Platinum drugs cisplatin, carboplatin and oxaliplatin are the frontline treatment options for a variety of localized as well as metastatic cancers.<sup>1</sup> However, their efficacy is often comprised due to inherent and acquired resistance in cancers. To circumvent this issue, we recently designed dual-targeting platinum-ferrocene (<strong>Pt-Fc</strong>) bimetallic hybrids with potent anticancer activity (manuscript submitted). The <strong>Pt-Fc</strong> derivative has much lower platinum cross-resistance compared to cisplatin, but was unable to circumvent the resistance completely.   Encouraged by the lack of cross-platinum resistance of ruthenium (Ru) compounds,<sup>2</sup> we synthesized a Ru-Fc derivative (<strong>1</strong>) and evaluated its anticancer potential <em>in vitro</em>. Moreover, we performed a structure activity relationship on this class of compound (<strong>1 - 6</strong>) to understand the role of various functionalities. We confirmed by comparing IC<sub>50</sub> values in platinum sensitive and resistance cancer cells that <strong>1</strong> has the ability to circumvent Pt resistance. In depth biological studies were performed to identify intracellular targets and mechanism of action of this promising anticancer drug candidate.  </p>
<p><strong>Reference</strong></p>
<ol>
<li>Kenny, R. G.; Marmion, C. J., Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens? <em> Rev. </em><strong>2019,</strong> <em>119</em> (2), 1058-1137.</li>
<li>Jyoti Yellol, Sergio A. Perez, ́ Alicia Buceta, Gorakh Yellol, Antonio Donaire, Piotr Szumlas, Patrick J. Bednarski., Gamall Makhloufi, Christoph Janiak, Arturo Espinosa,∥ and JoséRuiz*,† <em>Med.Chem</em>, <strong>2015</strong>, <em>58</em>, 7310-7327</li>
</ol>